Adoprazine hydrochloride | 222551-05-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Adoprazine hydrochloride
• 英文别名: 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]-methyl]piperazine monohydrochloride；1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)pyridin-3-yl]methyl]piperazine;hydrochloride
• CAS: 222551-05-5
• 化学式: C₂₄H₂₄FN₃O₂*ClH
• 分子量: 441.933
• InChiKey: PAPGPUNOWOEIPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Adoprazine hydrochloride 在 碳酸氢钠 、 间氯过氧苯甲酸 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 、 乙酸乙酯 为溶剂， 反应 2.5h， 以39%的产率得到SLV 313-piperazine-N-oxide
  参考文献：
  名称：

  WO2007/128694

  摘要：

  公开号：
• 作为产物：
  描述：

  1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 生成 Adoprazine hydrochloride
  参考文献：
  名称：

  Bibyclic heteroacrylpiperazine derivatives having psychotropic activity,

  摘要：

  本发明涉及具有精神活性的新组合物，其包括作为活性物质的公式表中的1号化合物。 公式1的化合物大部分是新化合物。 因此，本发明还涉及这些新化合物及其制备，其制备方法与类似化合物的合成方法相同。

  公开号：

  US05424313A1

文献信息

• Piperazine and piperidine compounds
  申请人：Duphar International Research B.V.

  公开号：US06090812A1

  公开（公告）日：2000-07-18

  A group of new piperazine and piperidine compounds having interesting advantageous pharmacological properties and have the formula (a) ##STR1## wherein A represents a heterocyclic group having 5-7 ring atoms wherein 1-3 heteroatoms selected from the group O, N and S are present, R.sub.1 is hydrogen or fluoro, R.sub.2 is C.sub.1-4 -alkyl, C.sub.1-4 -alkoxy or an oxo group, and p is 0, 1 or 2, Z represents carbon or nitrogen, and the dotted line represents a single bond when Z is nitrogen, and represents a single or double bond when Z is carbon, R.sub.3 and R.sub.4 independently are hydrogen or C.sub.1-4 -alkyl, n has the value 1 or 2, R.sub.5 is 2-pyridyl, 3-pyridyl or 4-pyridyl substituted at the meta-position with respect to the methylene bridge with a group Y, and optionally substituted with (R.sub.6)q, Y is a phenyl, furanyl or thienyl group, which groups may be substituted with 1-3 substituents from the group hydroxy, halogen, CF.sub.3, C.sub.1-4 -alkoxy, C.sub.1-4 -alkyl, cyano aminocarbonyl, mono- or di-C.sub.1-4 -alkylaminocarbonyl, R.sub.6 is halogen, hydroxy, C.sub.1-4 -alkoxy or C.sub.1-4 -alkyl, and q is 0, 1, 2 or 3 and salts thereof, are disclosed.

  一组新的哌嗪和哌啶类化合物具有有趣的优势药理特性，其化学式为（a）##STR1##其中A表示具有5-7个环原子的杂环基团，其中存在1-3个从O，N和S中选择的杂原子，R.sub.1是氢或氟，R.sub.2是C.sub.1-4-烷基，C.sub.1-4-烷氧基或氧代基，p为0，1或2，Z表示碳或氮，点线表示当Z为氮时为单键，当Z为碳时为单键或双键，R.sub.3和R.sub.4独立地是氢或C.sub.1-4-烷基，n的值为1或2，R.sub.5是在与亚甲基桥相对的间位上用Y基取代的2-吡啶基，3-吡啶基或4-吡啶基，可以选择地用（R.sub.6）q取代，Y是苯基，呋喃基或噻吩基，这些基团可以用羟基，卤素，CF.sub.3，C.sub.1-4-烷氧基，C.sub.1-4-烷基，氰基氨基甲酰基，单或双C.sub.1-4-烷基氨基甲酰基取代，R.sub.6是卤素，羟基，C.sub.1-4-烷氧基或C.sub.1-4-烷基，q为0，1，2或3以及其盐。
• Bibyclic heteroacrylpiperazine derivatives having psychotropic activity,
  申请人：Duphar International Research B.V.

  公开号：US05424313A1

  公开（公告）日：1995-06-13

  The invention relates to new compositions with pyschotropic activity which comprise a compound of formula 1 of the formula sheet as the active substance. The compounds of formula 1 are for the greater part new compounds. The invention therefore also relates to these new compounds and to the preparation thereof in a manner known for the synthesis of analogous compounds.

  本发明涉及具有精神活性的新组合物，其包括作为活性物质的公式表中的1号化合物。 公式1的化合物大部分是新化合物。 因此，本发明还涉及这些新化合物及其制备，其制备方法与类似化合物的合成方法相同。
• N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES
  申请人：Solvay Pharmaceuticals B.V.

  公开号：EP2024363A1

  公开（公告）日：2009-02-18
• N-OXIDES OF PYRIDYLMETHYL -PIPERAZINE AND -PIPERIDINE DERIVATIVES
  申请人：Van Aar P.M. Marcel

  公开号：US20070275977A1

  公开（公告）日：2007-11-29

  N-oxides of certain pyridylmethylpiperazine and -piperidine derivatives are provided as alternatives to or as “prodrugs” of their respective parent compounds, as well as pharmaceutical compositions containing these N-oxides, methods for preparing them, and compositions comprising them. The N-oxides have the formula (a) wherein the substituents have the meanings given in the description, and wherein the oxidized nitrogen atom can be the nitrogen atom in the pyridyl ring of R 5 , or the nitrogen atom in the piperidine ring (when Z is carbon) or either one of the nitrogen atoms in the piperazine ring (when Z is nitrogen), or both the nitrogen atom connected to R 5 via a methylene group, and the nitrogen atom in the pyridyl ring of R 5 , and tautomers, stereoisomers, pharmacologically acceptable salts, hydrates, and solvates thereof. In addition, the N-oxides and compositions can be used as medicaments useful in the treatment of affections or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotinergic systems.
• [EN] N-OXIDES OF PYRIDYLMETHYLPIPERAZINE AND -PIPERIDINE DERIVATIVES<br/>[FR] N-OXYDES DE DÉRIVÉS DE PYRIDYLMÉTHYLPIPÉRAZINE ET -PIPÉRIDINE
  申请人：SOLVAY PHARM BV

  公开号：WO2007128694A1

  公开（公告）日：2007-11-15

  [EN] The invention concerns N-oxides of certain pyridylmethylpiperazine and -piperidine derivatives as alternatives or as `prodrugs' of their respective parent compounds, to pharmaceutical compositions containing these N-oxides, to methods for preparing them, and methods for preparing compositions. The invention relates to N-oxides of compounds having formula (a), wherein the symbols have the meanings given in the description, and wherein the oxidized nitrogen atom may be the nitrogen atom in the pyridyl ring of R₅, or the nitrogen atom in the piperidine ring (when Z is carbon) or either one of the nitrogen atoms in the piperazine ring (when Z is nitrogen), or bóth the nitrogen atom connected to R₅ via a methylene group, ánd the nitrogen atom in the pyridyl ring of R₅, and tautomers, stereoisomers, pharmacologically acceptable salts, hydrates and solvates thereof. The invention also relates to the uses of such N-oxides and compositions, particularly for the manufacture of a medicament useful in the treatment of affections or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotinergic systems, for example Parkinson's disease, aggression, anxiety disorders, autism, vertigo, depression, disturbances of cognition or memory and in particular schizophrenia and other psychotic disorders.
  [FR] L'invention concerne des N-oxydes de certains dérivés de pyridylméthylpipérazine et -pipéridine en tant qu'alternatives ou en tant que = promédicaments = de leurs composés parents respectifs, des compositions pharmaceutiques contenant ces N-oxydes, leurs procédés de préparation et des procédés de préparation des compositions. L'invention concerne des N-oxydes de composés de formule (a), dans laquelle les symboles ont les significations données dans la description et dans laquelle l'atome d'azote oxydé peut être l'atome d'azote du cycle pyridyle de R₅ ou l'atome d'azote du cycle pipéridine (lorsque Z est un carbone) ou l'un quelconque des atomes d'azote du cycle pipérazine (lorsque Z est un azote) ou à la fois l'atome d'azote relié à R₅ par un groupement méthylène et l'atome d'azote du cycle pyridyle de R₅, ainsi que leurs tautomères, stéréoisomères, sels pharmacologiquement acceptables, hydrates et solvates. L'invention concerne également les utilisations de tels N-oxydes et de telles compositions, en particulier pour la fabrication d'un médicament utile pour le traitement d'affections ou de maladies du système nerveux central causées par des perturbations du système dopaminergique ou du système sérotinergique, par exemple la maladie de Parkinson, le comportement agressif, les troubles de l'anxiété, l'autisme, le vertige, la dépression, les troubles de la cognition ou de la mémoire, et en particulier la schizophrénie et d'autres troubles psychotiques.